Share Price | 180 Life Sciences Corp. Stock Analysis & Recommendation

Q: Is 180 Life Sciences Corp. technically bullish or bearish?

As of 28 August 2025, the technical trend for 180 Life Sciences Corp. has changed from bullish to mildly bullish. The current stance is mildly bullish, supported by daily moving averages and a bullish KST on the weekly timeframe. However, the weekly MACD is mildly bearish, and the monthly RSI indicates bearish momentum. The Bollinger Bands are mildly bullish on both weekly and monthly charts, suggesting some upward potential. In terms of performance, the stock has returned 4.15% over the past week compared to the S&P 500's 1.05%, but it has seen a significant decline of 66.13% over the past month against the S&P's 2.33%. Year-to-date, the stock is up 37.91%, outperforming the S&P 500's 12.22%. Overall, while there are some bullish indicators, the mixed signals suggest caution.

Q: What does 180 Life Sciences Corp. do?

Overview:180 Life Sciences Corp. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap company.Financial Snapshot:- Most recent Net Profit: -2 Million (Quarterly Results - Mar 2025)- Market cap: USD 5.29 Million (Micro Cap)Key Metrics:- P/E: NA (Loss Making)- Industry P/E: NA- Dividend Yield: 0.00%- Debt Equity: -0.46- Return on Equity: -42.26%- Price to Book: 0.69Contact Details:Details: No Company Details AvailableRegistrar Address: Not available.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

168.06 k

Shareholding (Mar 2026)

FII

3.37%

Held by 18 FIIs

DII

88.28%

Held by 5 DIIs

Promoter

8.36%

Is 180 Life Sciences Corp. technically bullish or bearish?

20-Sep-2025

As of August 28, 2025, 180 Life Sciences Corp. shows a mildly bullish trend with mixed signals, having gained 4.15% over the past week but down 66.13% in the last month, while year-to-date it is up 37.91%, outperforming the S&P 500's 12.22%.

View full answer

How big is 180 Life Sciences Corp.?

22-Jun-2025

As of Jun 18, 180 Life Sciences Corp. has a market capitalization of 5.29 million, with net sales of 0.00 million and a net profit of -7.47 million. Shareholder's funds were 9.25 million, and total assets amounted to 33.51 million.

View full answer

What does 180 Life Sciences Corp. do?

22-Jun-2025

180 Life Sciences Corp. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $2 million and a market cap of $5.29 million. Key metrics include a negative P/E ratio, no dividend yield, and a price-to-book ratio of 0.69.

View full answer

Compare 180 Life Sciences Corp. with Similar Stocks

Plus Therapeutics, Inc.Panbela Therapeutics, Inc.ABVC BioPharma, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Poor Management Efficiency with a low ROE of 0%

The company has reported losses. Due to this company has reported negative ROE

The company has declared Negative results for the last 4 consecutive quarters

Risky -

Consistent Underperformance against the benchmark over the last 3 years

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 53 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.03

Return on Equity

-50.58%

Price to Book

0.12

Revenue and Profits:

Net Sales:

3 Million

(Quarterly Results - Mar 2026)

Net Profit:

-78 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

79.72%

6 Months

-20.6%

1 Year

-42.62%

2 Years

-69.21%

3 Years

-97.73%

4 Years

-99.84%

5 Years

-99.99%

180 Life Sciences Corp. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-1.00%

EBIT Growth (5y)

-329.35%

EBIT to Interest (avg)

-6.60

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.46

Sales to Capital Employed (avg)

0.01

Tax Ratio

4.58%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

45.48%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.12

EV to EBIT

-0.18

EV to EBITDA

-0.18

EV to Capital Employed

0.09

EV to Sales

9.86

PEG Ratio

Dividend Yield

ROCE (Latest)

-52.20%

ROE (Latest)

-50.58%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bearish

Bollinger Bands

Mildly Bearish

Bearish

Moving Averages

Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2026

Shareholding Compare (%holding)

Majority shareholders

Strategic Entities

Domestic Funds

Held in 5 Schemes (3.66%)

Foreign Institutions

Held by 18 Foreign Institutions (3.37%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Mar 2026 is 0.00% vs 0.00% in Mar 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Mar 2026 is -3,129.17% vs -118.18% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2.90",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-4.20",
          "val2": "-2.40",
          "chgp": "-75.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "1.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-65.90",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-77.50",
          "val2": "-2.40",
          "chgp": "-3,129.17%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-1,620.50%",
          "val2": "0.00%",
          "chgp": "-162.05%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -16,957.69% vs 86.93% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "6.50",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-233.40",
          "val2": "-4.40",
          "chgp": "-5,204.55%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "3.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-206.50",
          "val2": "0.10",
          "chgp": "-2,06,600.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-443.50",
          "val2": "-2.60",
          "chgp": "-16,957.69%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-35,657.60%",
          "val2": "0.00%",
          "chgp": "-3,565.76%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY

Mar'26

Mar'25

Change(%)

Net Sales

2.90

0.00

Operating Profit (PBDIT) excl Other Income

-4.20

-2.40

-75.00%

Interest

1.00

0.00

Exceptional Items

-65.90

0.00

Consolidate Net Profit

-77.50

-2.40

-3,129.17%

Operating Profit Margin (Excl OI)

-1,620.50%

0.00%

-162.05%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Mar 2026 is 0.00% vs 0.00% in Mar 2025

Consolidated Net Profit

YoY Growth in quarter ended Mar 2026 is -3,129.17% vs -118.18% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

6.50

0.00

Operating Profit (PBDIT) excl Other Income

-233.40

-4.40

-5,204.55%

Interest

3.10

0.00

Exceptional Items

-206.50

0.10

-2,06,600.00%

Consolidate Net Profit

-443.50

-2.60

-16,957.69%

Operating Profit Margin (Excl OI)

-35,657.60%

0.00%

-3,565.76%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -16,957.69% vs 86.93% in Dec 2024

All Annual Results

Company CV

About 180 Life Sciences Corp.

180 Life Sciences Corp.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available